- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00990236
Thrombelastography Based Dosing of Enoxaparin
Thrombelastography Based Dosing of Enoxaparin for Thromboprophylaxis: a Prospective Randomized Trial
The risk of developing a blood clot occurs in up to 60% of all critical care patients. Many times enoxaparin (or Lovenox®) is given to patients who are at a higher risk of developing clots in their legs or lungs. Recent data suggest that a standard dose of Lovenox may not fully prevent the development of these clots especially in critically ill or obese patients. Routine enoxaparin dosing can also result in bleeding complications. Thrombelastography (TEG®) can be used to measure how blood clots. The purposes of this study are:
- to learn if the TEG® can better guide physicians in prescribing an effective dose of Lovenox compared to standard doses recommended by the drug company in preventing blood clots from developing in the legs and lungs, and
- to compare the development of blood clots in patients receiving the standard dose of enoxaparin compared to patients receiving a TEG® guided dose of enoxaparin.
- to determine if TEG guided dosing results in decreased bleeding complications compared to standard dosing.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Hypothesis:
Enoxaparin dosed to maintain a TEG® ΔR greater than 1.0 minute will decrease the incidence of DVT compared to standard dosing.
Initiation of enoxaparin thromboprophylaxis will be done by the treatment team. Once enrolled, the subject will be randomized to continue receiving standard dose enoxaparin (30 mg twice daily) or variable TEG® guided enoxaparin dosing. The treatment team and the subject will be blinded regarding the arm in which the patient is enrolled. Patient characteristics: age, gender, body mass index (BMI), comorbidities, Acute Physiology and Chronic Health Evaluation II score (APACHE II), injuries, and operations will be collected. As part of standard protocol in the ICU, all patients will undergo weekly ultrasound duplex examination of the lower extremities for presence of deep venous thrombosis.
A baseline TEG® will be completed on each patient when they are enrolled in the study. The blood will be drawn between four and six hours after the morning dose is administered, corresponding to maximum tissue levels of enoxaparin. TEG® assays will be run in duplicate for each patient, with and without heparinase, which negates the effects of enoxaparin in the assay.
Those patients randomized to the control arm of the study will have TEG® performed at baseline and daily for one week, then twice weekly. The twice weekly TEG® assays will be done until the patient is discharged from inpatient care or enoxaparin is discontinued by the treatment team. No adjustments will be made to their enoxaparin dosing.
Patients in the TEG® guided enoxaparin dosing arm will start treatment as ordered by the primary treatment team. After the second TEG®, the dose of enoxaparin will be adjusted in 10 mg increments per dose in order to reach a target ΔR between 1.0 and 1.4 minutes. If the initial ΔR is greater than 1.4 minutes, the dose of enoxaparin will be decreased by 10 mg increments until the target ΔR is achieved. Patients will have TEGs® performed daily and adjustment of dosing until the target ΔR is reached. Once the target ΔR is achieved, TEG® will be done twice weekly until the patient is discharged from inpatient care or enoxaparin is discontinued by the treatment team. All patients will be assessed daily by study personnel for bleeding complications. If bleeding complications occur, subjects will be withdrawn from the study. If interim analysis identifies a significant difference in bleeding complications between groups the study will be terminated.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Oregon Health & Science University
-
-
Texas
-
Houston, Texas, United States
- University of Texas Health Science Center at Houston
-
-
Washington
-
Seattle, Washington, United States
- University of Washington
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Inpatient initiated on enoxaparin thromboprophylaxis
- Age greater than 15 years
Exclusion Criteria:
- Unable to obtain consent from patient or ARR
- Presence of: intracranial hemorrhage, brain injury
- Receiving therapeutic dose enoxaparin
- Receiving other forms of anticoagulation
- Receiving non-standard dosing regimen of enoxaparin
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Enoxaparin 30 mg BID
standard dose enoxaparin thromboprophylaxis (30 mg twice daily)
|
Enoxaparin dose of 30 mg twice a day without any adjustments
Other Names:
|
Experimental: Enoxaparin dose adjusted based on TEG
enoxaparin dose modified based on TEG results
|
Enoxaparin doses will be adjusted (10 mg BID) based on delta-R results from TEG. Delta-R < 1.0 min - increase dose by 10 mg BID; delta-R >/= 1.0 min and 2.0 min - decrease dose by 10 mg BID.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Development of Deep Vein Thrombosis (DVT)
Time Frame: Through study completion, assessed up to 120 days post randomization
|
An ultrasound duplex will be completed at least one time after randomization to determine if the subject has developed a DVT.
|
Through study completion, assessed up to 120 days post randomization
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Bleeding Complications
Time Frame: Through study completion, assessed up to 120 days post randomization
|
An increase in bleeding complications will be assessed daily during hospitalization
|
Through study completion, assessed up to 120 days post randomization
|
Collaborators and Investigators
Investigators
- Principal Investigator: Martin Schreiber, MD FACS, Oregon Health and Science University
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 001-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Thromboembolic Complications
-
Hvidovre University HospitalCompletedBlood Loss | Postoperative Blood Loss | Thromboembolic ComplicationsDenmark
-
University Hospital, GenevaCompleted
-
CHU de ReimsCompletedThromboembolic EventFrance
-
Emory UniversityNational Association of Orthopaedic NursesCompleted
-
Direction Centrale du Service de Santé des ArméesRecruitingVenous Thromboembolic DiseaseFrance
-
Qianfoshan HospitalNot yet recruitingVenous Thromboembolic DiseaseChina
-
ThromboGenicsBioInvent International ABCompletedProphylaxis of Venous Thromboembolic EventsAustria, Netherlands, Belgium, Bulgaria, Hungary, Latvia, Poland, Russian Federation, Ukraine
-
Centre Hospitalier Universitaire de Saint EtienneCompleted
-
University Hospital, Strasbourg, FranceRecruitingVenous Thromboembolic DiseaseFrance
-
Odense University HospitalCompletedVenous Thromboembolic DiseaseDenmark
Clinical Trials on Enoxaparin 30 mg BID
-
Oregon Health and Science UniversityRecruitingTrauma | Surgery | Deep Vein Thrombosis (DVT) | Thromboembolic EventsUnited States
-
University of CincinnatiUnited States Air ForceCompletedVenous Thromboembolism | Traumatic InjuryUnited States
-
PfizerCompleted
-
Pirogov Russian National Research Medical UniversityRecruitingVenous ThromboembolismRussian Federation
-
King Abdullah International Medical Research CenterCompleted
-
Vifor (International) Inc.Labcorp Drug Development IncWithdrawnBeta-ThalassemiaUnited States, Bulgaria, Israel
-
AstraZenecaCompletedParkinson's DiseaseUnited States
-
Innovation Pharmaceuticals, Inc.CompletedChronic Stable Plaque PsoriasisUnited States
-
PfizerTerminated
-
Merck Sharp & Dohme LLCCompleted